# New lymphoma clinical trials, last 30 days: 47 (2026)

Updated November 19, 2026.

47 new trials for lymphoma were first posted on ClinicalTrials.gov in the 30 days from October 20, 2026 to November 18, 2026, as read on November 19, 2026.

## The full list

New lymphoma clinical trials, last 30 days: 47 rows for $5, first posted from October 20, 2026 to November 18, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 7 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/new/lymphoma

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 47
- Recruiting or not yet: 44
- Read on: November 19, 2026

## Trials

The 25 newest of 47, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 18, 2026 | NCT07945470 | Simulation-Free Single-Fraction Radiation Therapy for Indolent Lymphoma | University Health Network, Toronto | Not applicable | Recruiting | Indolent B-Cell Non-Hodgkin Lymphoma, Marginal Zone Lymphoma, Follicular Lymphoma, Small Lymphocytic Lymphoma, Mantle... | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07945470) |
| November 18, 2026 | NCT07945353 | Orelabrutinib Plus 4 Gy Radiotherapy Versus 24 Gy Radiotherapy for Stage I/II MALT Lymphoma | Fudan University | Phase 2 | Not yet recruiting | MALT Lymphoma | 272 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07945353) |
| November 18, 2026 | NCT07944651 | Pirtobrutinib With Sonrotoclax and Rituximab for High-Risk Relapsed/Refractory Mantle-Cell Lymphoma Following Covalent BTK-Inhibitor Failure | Tianjin Medical University Cancer Institute and Hospital | Phase 2 | Not yet recruiting | Mantle Cell Lymphoma (MCL), Relapsed/Refractory Mantle Cell Lymphoma (MCL) | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07944651) |
| November 17, 2026 | NCT07941531 | T-Cell Therapy Using CD7 Negative T-Cells Expressing CD7 CAR Expressed In Pediatric Patients With Hematological Malignancies. | St. Jude Children's Research Hospital | Phase 1 | Not yet recruiting | Lymphoma, AML, T-ALL, Hematologic Malignancy | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07941531) |
| November 17, 2026 | NCT07941492 | A Trial of FHD-286 Plus Mosunetuzumab in Previously Treated Follicular Lymphoma | Weill Medical College of Cornell University | Phase 1 | Not yet recruiting | Follicular Lymphoma | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07941492) |
| November 17, 2026 | NCT07941063 | Multimodal Ultrasound for Lymphoma Classification and Treatment Response Prediction | Chinese PLA General Hospital | Observational | Recruiting | Lymphoma, Hodgkin Lymphoma, Non-Hodgkin Lymphoma | 2,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07941063) |
| November 16, 2026 | NCT07939685 | Entinostat + R-CHOP in Newly Diagnosed MYC/BCL2 Double-Expressor DLBCL: Phase II Trial | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Diffuse Large B-Cell Lymphoma (DLBCL) | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07939685) |
| November 16, 2026 | NCT07938619 | Tafasitamab, Lenalidomide, Rituximab, and Orelabrutinib for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Sun Yat-sen University | Phase 2 | Not yet recruiting | Diffuse Large B Cell Lymphoma (DLBCL) | 29 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07938619) |
| November 16, 2026 | NCT07937566 | Observational Study to Evaluate the Clinical Impact of BTK Inhibitor-Based Regimens in Treatment-Naïve Patients With Mantle Cell Lymphoma... | Fondazione Italiana Linfomi - ETS | Observational | Not yet recruiting | Mantle Cell Lymphoma | 500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07937566) |
| November 13, 2026 | NCT07936266 | Asciminib and Inotuzumab Ozogamicin for Relapsed or Refractory Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia (R/R... | Sponsor not shown (see the record) | Phase 1 | Recruiting | B-cell Acute Lymphoblastic Leukemia (B-ALL) | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07936266) |
| November 13, 2026 | NCT07934537 | Efficacy and Safety of Chidamide Combined With PD-1 Inhibitor as Maintenance Therapy Following CAR-T Cell Treatment With TP53-Mutated Large... | Shanghai Tongji Hospital, Tongji University School of Medicine | Phase 4 | Recruiting | Large B-Cell Lymphoma (LBCL), Lymphoma, Large B-Cell, Diffuse | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07934537) |
| November 12, 2026 | NCT07932730 | Disulfiram for Preventing Treatment Complications in Patients Undergoing CAR T-cell Therapy for Relapsed or Refractory Diffuse Large B-cell... | University of Michigan Rogel Cancer Center | Phase 1/2 | Not yet recruiting | Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07932730) |
| November 10, 2026 | NCT07927816 | CD19 Sequential CD22 In Vivo CAR-T Cell Immunotherapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia | Sponsor not shown (see the record) | Phase 1 | Recruiting | Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia, In Vivo CAR-T, B-Cell Acute Lymphoblastic Leukemia | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07927816) |
| November 6, 2026 | NCT07921615 | QLS4131 Plus Isa-V-CHOP in Newly Diagnosed, HIV-Negative PBL: A Single-Center, Single-Arm, Phase II Study | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 | Not yet recruiting | Plasmablastic Lymphoma | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07921615) |
| November 6, 2026 | NCT07920757 | Multi-omics Profiling of Relapsed Extranodal Natural Killer (NK)/T-cell Lymphoma | Fujian Medical University Union Hospital | Observational | Active not recruiting | Extranodal NK/T-cell Lymphoma, Nasal Type | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07920757) |
| November 5, 2026 | NCT07920393 | Allogeneic Cell Therapy in Refractory T-Cell Lymphoma | University Medical Center Goettingen | Phase 2 | Not yet recruiting | Lymphoma, T Cell, Peripheral | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07920393) |
| November 5, 2026 | NCT07917832 | Smart 3: A Multi-Center Phase 2 Trial Of Golcadomide, Glofitamab And Polatuzumab Vedotin (G2P) For Patients With Newly Diagnosed Large... | M.D. Anderson Cancer Center | Phase 2 | Not yet recruiting | Multi Center, Phase 2, Golcadomide, Glofitamab, Polauzumab, Vedotin, G2p, B Cell Lymphoma | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07917832) |
| November 5, 2026 | NCT07917754 | A Clinical Trial of MK-1045 With Zilovertamab Vedotin in Participants With Diffuse Large B-cell Lymphoma (MK-1045-010) | Merck Sharp & Dohme LLC | Phase 2/3 | Not yet recruiting | Lymphoma, Large B-Cell, Diffuse, Diffuse Large B-Cell Lymphoma | 470 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07917754) |
| November 4, 2026 | NCT07917650 | PET/CT-Guided Maintenance Therapy in Previously Untreated MZL | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 | Active not recruiting | Marginal Zone Lymphoma(MZL) | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07917650) |
| November 4, 2026 | NCT07917624 | Prophylactic Strategies for Mitigating Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 | Not yet recruiting | Diffuse Large B-Cell Lymphoma (DLBCL) | 87 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07917624) |
| November 3, 2026 | NCT07914348 | Evaluation of LB-208 (HTR1B Antagonist) in Adult Patients With Relapsed or Refractory Solid Tumours and Lymphoma | Leukos Biotech S.L. | Phase 1 | Recruiting | Solid Tumor Malignancies, Lymphoma | 57 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07914348) |
| November 3, 2026 | NCT07912684 | The Value of a Tailored-based, Exercise Program for Improving Quality of Life of Patients With Hematologic Malignancies: a Pilot Randomized... | Gruppo Italiano Malattie EMatologiche dell'Adulto | Not applicable | Recruiting | Acute Myeloid Leukemia, Multiple Myeloma, Lymphoma | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07912684) |
| November 2, 2026 | NCT07911553 | A Study to Evaluate Surovatamig Combined With R-CHOP in Participants of 18 to \< 80 Years of Age With Previously Untreated Large B-cell... | AstraZeneca | Phase 3 | Not yet recruiting | Large B-cell Lymphoma | 1,200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07911553) |
| November 2, 2026 | NCT07910708 | GN001 for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and B-Cell Acute Lymphoblastic Leukemia | Department of Hematology,Rheumatology and Immunology,Pu'er People's Hospital | Phase 1 | Recruiting | Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07910708) |
| November 2, 2026 | NCT07910435 | Polatuzumab Vedotin, Mosunetuzumab, and Acalabrutinib for the Treatment of Mantle Cell Lymphoma, PAcMan Trial | University of Washington | Phase 2 | Not yet recruiting | Mantle Cell Lymphoma | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07910435) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 11 |
| Phase 1/2 | 6 |
| Phase 2 | 15 |
| Phase 2/3 | 1 |
| Phase 3 | 2 |
| Phase 4 | 2 |
| Not applicable | 3 |
| Observational | 7 |

## Sponsors posting most

| Sponsor | Trials |
| --- | --- |
| Chinese PLA General Hospital | 2 |
| University of Michigan Rogel Cancer Center | 2 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 2 |
| University Health Network, Toronto | 1 |
| Fudan University | 1 |
| Tianjin Medical University Cancer Institute and Hospital | 1 |
| St. Jude Children's Research Hospital | 1 |
| Weill Medical College of Cornell University | 1 |
| Sun Yat-sen University | 1 |
| Fondazione Italiana Linfomi - ETS | 1 |
| Shanghai Tongji Hospital, Tongji University School of Medicine | 1 |
| Institute of Hematology & Blood Diseases Hospital, China | 1 |
| Fujian Medical University Union Hospital | 1 |
| University Medical Center Goettingen | 1 |
| M.D. Anderson Cancer Center | 1 |
| [Merck Sharp & Dohme LLC](https://specstream.ai/data/clinical-trials/company/merck-sharp-and-dohme-llc) | 1 |
| Leukos Biotech S.L. | 1 |
| Gruppo Italiano Malattie EMatologiche dell'Adulto | 1 |
| Department of Hematology,Rheumatology and Immunology,Pu'er People's Hospital | 1 |
| University of Washington | 1 |
| The First Hospital of Jilin University | 1 |
| Istituto Oncologico Veneto IRCCS | 1 |
| Beijing Kangchuanglian Biopharmaceutical Technology Research Co., Ltd | 1 |
| Medsyn Biopharma, LLC | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [IT companies in the United States](https://specstream.ai/data/businesses/it-companies/united-states)
- [Eye care clinics in the United States](https://specstream.ai/data/businesses/eye-care-clinics/united-states)
- [Caterers in the United States](https://specstream.ai/data/businesses/caterers/united-states)
- [Allergy and immunology practices in the United States](https://specstream.ai/data/businesses/allergy-and-immunology-practices/united-states)
- [Speech therapy clinics in the United States](https://specstream.ai/data/businesses/speech-therapy-clinics/united-states)
- [Payroll companies in the United States](https://specstream.ai/data/businesses/payroll-companies/united-states)
